key: cord-0902606-uwylnfap
authors: Hauser, Blake M.; Sangesland, Maya; Lam, Evan C.; Feldman, Jared; Yousif, Ashraf S.; Caradonna, Timothy M.; Balazs, Alejandro B.; Lingwood, Daniel; Schmidt, Aaron G.
title: Engineered receptor binding domain immunogens elicit pan-coronavirus neutralizing antibodies
date: 2020-12-08
journal: bioRxiv
DOI: 10.1101/2020.12.07.415216
sha: 05a509ac52b21e256e7d33b3ffa30a35d2c7694b
doc_id: 902606
cord_uid: uwylnfap

Effective countermeasures are needed against emerging coronaviruses of pandemic potential, similar to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Designing immunogens that elicit broadly neutralizing antibodies to conserved viral epitopes on the major surface glycoprotein, spike, such as the receptor binding domain (RBD) is one potential approach. Here, we report the generation of homotrimeric RBD immunogens from different sarbecoviruses using a stabilized, immune-silent trimerization tag. We find that that a cocktail of homotrimeric sarbecovirus RBDs can elicit a neutralizing response to all components even in context of prior SARS-CoV-2 imprinting. Importantly, the cross-neutralizing antibody responses are focused towards conserved RBD epitopes outside of the ACE-2 receptor-binding motif. This may be an effective strategy for eliciting broadly neutralizing responses leading to a pan-sarbecovirus vaccine.

The emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 57 the subsequent global pandemic has highlighted the disruptive threat posed by viruses for which 58 humans have no prior immunity. Rapid development of potential vaccines has led to an 59 unprecedented 13 candidates already in Phase 3 clinical trials in the last 6 months; while differing 60 in modality (e.g., mRNA, adenovirus), the primary immunogen for many of these candidates is 61 the SARS-CoV-2 spike ectodomain (1). With the continued global spread of SARS-CoV-2, in 62 conjunction with potential vaccinations, it is likely that a large proportion of the global population 63 will eventually develop an immune response to SARS-CoV-2. However, even after potentially 64 achieving herd immunity sufficient to slow the spread of SARS-CoV-2, there remains a constant 65 threat of emerging coronaviruses with pandemic potential. Indeed, surveillance efforts have 66 identified numerous unique coronaviruses within various animal reservoirs, raising the possibility 67 of zoonotic transmission (2, 3) . Such events are likely to increase in frequency as a result of human 68 impact on the environment (4). While the current SARS-CoV-2 pandemic has an estimated 69 infection fatality rate of between ~1-2%, with numerous cases likely undetected, previous SARS-70

CoV and MERS-CoV outbreaks were more lethal with ~10% and ~35% case fatality rates, 71 respectively, raising the possibility that future novel coronaviruses have potentially high mortality 72

(5-7). Additionally, elicited immunity to SARS-CoV-2 infection may not protect against even 73 closely related novel coronaviruses from the same sarbecovirus subgenus (8). It is therefore critical 74

to not only address the current pandemic, but also develop vaccine platforms that can be readily 75 adapted to potential emerging coronaviruses. 76 77 While we cannot readily predict which coronaviruses will next emerge into the human population, 78 a proactive approach to generate broadly protective immunity is to design immunogens that elicit 79 humoral responses targeting conserved sites on the coronavirus spike glycoprotein. Such sites may 80 include the receptor binding domain which engages host-cell receptors necessary to facilitate viral 81 cell entry; these spike-mediated interactions are conserved across coronaviruses (9). Indeed, a 82 subset of spike-directed antibodies from convalescent patients can potently neutralize SARS-CoV-83 2; comparable neutralizing antibodies against SARS-CoV and MERS-CoV have also been 84 identified (6, 10-15). Some spike-directed antibodies that neutralize SARS-CoV-2 also bind the 85 versus trimeric RBDs. Our experimental arms both received the spike prime and included a SARS-118

CoV-2 RBD homotrimer boost ("homotrimer" cohort) and an equimolar boosting cocktail of 119 SARS-CoV-2, SARS-CoV, and WIV1-CoV RBD homotrimers ("cocktail" cohort) (Figure 2A) . 120

All cohorts received the same total amount of protein in each immunization. We evaluated the 121 serum response against coronavirus-derived antigens using ELISAs (Figure 2B-C, S3) . All four 122 immunization regimens resulted in similar patterns of serum reactivity. Each cohort demonstrated 123 a significant decrease in reactivity against SARS-CoV RBD as compared to the SARS-CoV-2 124 RBD or spike, though the magnitude of this difference was relatively small. The cohort which 125 received the RBD homotrimer cocktail boost had the highest overall endpoint titers, while the 126 cohort that received the monomeric SARS-CoV-2 RBD had the lowest overall endpoint titers; the 127 latter observation is consistent with other previous reports and likely due to the inefficiency of 128 monomeric RBDs effectively stimulating B cell receptors. We confirmed the non-immunogenic 129 nature of the hyperglycosylated GCN4 tag by assaying sera from the wildtype homotrimer cocktail 130 boost against another viral glycoprotein, hemagglutinin, with the same tag ( Figure S4) . 131 132 We next evaluated whether the serum response was directed towards cross-reactive, and 133 potentially broadly neutralizing RBD epitopes. Conservation across SARS-CoV-2, SARS-CoV, 134 and WIV1-CoV RBDs primarily occurs outside of the ACE-2 receptor binding motif (RBM) 135 ( Figure S5A) . Indeed, the previously characterized CR3022 and S309 antibodies have footprints 136 that together cover much of this conserved region, with epitope buried surface area (BSA) of 917 137 Å 2 and 795 Å 2 respectively in comparison to BSA of 869 Å 2 for ACE-2 (16, 17, 24). We performed 138 serum competition by incubating RBD-coated ELISA plates with IgGs B38, P2B-2F6, CR3022, 139 and S309, representing each of the four previously defined "classes" of SARS-CoV-2 RBD 140 epitopes (25) (Figure S5B) . We then assessed binding of mouse serum IgG. In all cohorts, 141 competition with both CR3022 and S309 significantly reduced serum titers against the SARS-CoV 142 and WIV1-CoV RBDs ( Figure 2D) . However, only the cohort receiving the RBD homotrimer 143 cocktail showed a significant reduction in serum titers against the SARS-CoV-2 RBD in 144 competition with both CR3022 and S309 (p = 0.0340) ( Figure 2D) . This result suggests a higher 145 degree of focusing to this region elicited specifically by the homotrimer cocktail immunogens. 146

To compare to the observed sera responses, we measured the IgG B cell receptors expanded by 148 the immunization regimens. We engineered a SARS-CoV-2 RBD variant that has two additional 149 glycans on the RBM which effectively block ACE-2 engagement ( Figure S6 ). This variant 150 allowed us to bin SARS-CoV-2 spike-directed B cells into 3 populations: those that bound RBM 151 epitopes; those that bound the non-RBM epitopes on the RBD; and those that bound the 152 "remainder" of the spike protein ( Figure S7) . As a subset of SARS-CoV-2 spike-directed B cells, 153 the proportion of B cells specific for the SARS-CoV-2 RBM and non-RBM portion of the RBD 154 were considerably higher in the cohorts receiving the SARS-CoV-2 RBD homotrimer and RBD 155 homotrimer cocktail boosts (p = 0.0070) ( Figure 3A) . We also binned B cells that bound to both 156 the SARS-CoV-2 spike and either the SARS-CoV RBD or WIV1-CoV RBD ( Figure 3B ). We Here, we demonstrate that a cocktail of homotrimeric sarbecovirus RBDs can effectively generate 184 a neutralizing response to all components without a bias resulting from a SARS-CoV-2 imprinting 185 and without compromising SARS-CoV-2 neutralization. We find that this cross-neutralizing 186 antibody response is predominantly directed to RBD epitopes outside of the RBM. This is in 187 contrast to SARS-CoV-2 infection which does not appear to reliably generate cross-neutralizing 188 antibodies (8). Furthermore, previously reported vaccine candidates that aim to generate such a 189 cross-neutralizing response have not been shown to successfully refocus immunity towards cross-190 neutralizing epitopes following an initial SARS-CoV-2 spike immunization (26). However, our 191 results suggest that following an initial SARS-CoV-2 exposure (e.g., commercial vaccination, 

SARS-CoV-2 Vaccines: Status Report

Global patterns in coronavirus diversity

Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage 387 responsible for the COVID-19 pandemic

Committee on Achieving Sustainable Global Capacity for 389 Surveillance and Response to Emerging Diseases of Zoonotic Origin, Sustaining Global 390 Surveillance and Response to Emerging Zoonotic Diseases

Neutralizing Antibodies against SARS-CoV-2 and Other 393 Human Coronaviruses

The spike protein of SARS-CoV--a target for vaccine and therapeutic 395 development

Estimating the infection-fatality risk of SARS-CoV-2 in New York City 397 during the spring 2020 pandemic wave: a model-based analysis

COVID-19 neutralizing antibodies predict disease severity and 399 survival. medRxiv

Fields virology

Broad neutralization of SARS-related viruses by human monoclonal 403 antibodies

Structural basis of a shared antibody response to SARS-CoV-2

Potently neutralizing and protective human antibodies against SARS-CoV-407 2

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection 409 from disease in a small animal model

A noncompeting pair of human neutralizing antibodies block COVID-19 411 virus binding to its receptor ACE2

MERS-CoV spike protein: a key target for antivirals

A highly conserved cryptic epitope in the receptor binding domains of 415 SARS-CoV-2 and SARS-CoV

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV 417 antibody

A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, 419 and SARS

SARS-like WIV1-CoV poised for human emergence

Antibody landscapes after influenza virus infection or vaccination

Immunosilencing a 425 highly immunogenic protein trimerization domain

Immunogenicity and structures of a rationally designed prefusion MERS-427 CoV spike antigen

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen 429 preparedness

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the 431 ACE2 receptor

SARS-CoV-2 neutralizing antibody structures inform therapeutic 433 strategies

Mosaic RBD nanoparticle elicit neutralizing antibodies against SARS-435

CoV-2 and zoonotic coronaviruses. bioXriv

A general method for the covalent labeling of fusion proteins with small 437 molecules in vivo

Immunogenic Stimulus for Germline Precursors of Antibodies that 439 Engage the Influenza Hemagglutinin Receptor-Binding Site

Viral receptor-binding site antibodies with diverse germline origins

Germline-Encoded Affinity for Cognate Antigen Enables Vaccine 444 Amplification of a Human Broadly Neutralizing Response against Influenza Virus

In vitro reconstitution of B cell receptor-antigen interactions to 447 evaluate potential vaccine candidates

Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers 449 in COVID-19

Retroviruses pseudotyped with the severe acute respiratory syndrome 451 coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 452

Exceptionally potent neutralization of Middle East respiratory syndrome 454 coronavirus by human monoclonal antibodies

Affordable luciferase reporter assay for cell-based high-456 throughput screening

SARS-CoV-2-specific IgG B cells expanded following immunization. (A) Spike-488 directed responses were binned into RBM, RBD remainder (excluding RBM epitopes), and spike 489 remainder (excluding RBD and RBM epitopes) populations using relevant probes in flow 490 cytometry. Data is shown as a percentage of total spike-specific IgG B-cells. We evaluated the 491 distribution of SARS-CoV-2 spike-directed responses and found evidence of focusing towards 492

non-spike RBD epitopes in the cohorts boosted with the SARS-CoV-2 RBD homotrimer and the 493

RBD homotrimer cocktail versus the cohort that received three SARS-CoV-2 spike immunizations 494 (p = 0.0070 via Mann-Whitney U test) (A). (B) The cocktail cohort was additionally assayed for 495

SARS-CoV or WIV1-CoV RBD reactivity, as described in (A)